Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anidulafungin - Pfizer

Drug Profile

Anidulafungin - Pfizer

Alternative Names: Ecalta; ECB; Eraxis; LY303366; PF-3910960; V-echinocandin; VEC; VER 002; VER-02

Latest Information Update: 30 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Pfizer
  • Class Antifungals; Cyclic peptides
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Candidiasis

Highest Development Phases

  • Marketed Candidaemia; Candidiasis
  • No development reported Invasive bronchopulmonary aspergillosis
  • Discontinued Pneumocystis pneumonia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Feb 2018 Pfizer completes a phase III trial in Candidiasis/Candidaemia (In infants, In children, In adolescents) in USA, Brazil, Canada, Greece, Germany, France, Portugal, Spain, Italy, South Korea, Russia, Taiwan and United Kingdom (IV) (NCT00761267)
  • 16 Jan 2018 Anidulafungin is still in phase III trials for Candidiasis and Candidaemia (In adolescents, In children, In infants) in Brazil, Canada, France, Germany, Greece, Italy, Portugal, Russia, South Korea, Spain, Taiwan, United Kingdom and USA (IV) (NCT00761267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top